Key Protein Enrichment Patent Upheld for Seer, Protecting Core Proteograph Platform from Competitor Challenge
SEER is trading near its 52-week low of $1.62 (4.9% above the low).
Summary
The Patent Trial and Appeal Board (PTAB) has upheld 23 claims of Seer's U.S. Patent No. 11,435,360, which covers methods for protein enrichment using nano- and microparticles, a core technology for its Proteograph® Product Suite. This decision comes after a challenge initiated by subsidiaries of Bruker Corporation. The upholding of this patent is a significant positive development for Seer, validating and securing the intellectual property underpinning its primary product platform. This strengthens the company's competitive position in the proteomics market and removes a potential legal and operational risk, which is particularly material for a company of Seer's size and current stock performance. Investors will now watch for continued execution on product development and commercialization, with the added security of this key IP protection.
At the time of this announcement, SEER was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $93.7M. The 52-week trading range was $1.62 to $2.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.